(4S)-5-[4-(N,N-dimethylglycyl)piperazin-1-yl]-5-oxo-4-([(6-phenylpyridin-2-yl)carbonyl]amino)pentanoic acid | 1214283-92-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (4S)-5-[4-(N,N-dimethylglycyl)piperazin-1-yl]-5-oxo-4-([(6-phenylpyridin-2-yl)carbonyl]amino)pentanoic acid
• CAS: 1214283-92-7
• 化学式: C₂₅H₃₁N₅O₅
• 分子量: 481.552
• InChiKey: SFPPHONTPFSGAM-NRFANRHFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.94
• 重原子数：
  35.0
• 可旋转键数：
  9.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  123.15
• 氢给体数：
  2.0
• 氢受体数：
  6.0

反应信息

• 作为产物：
  描述：

  tert-butyl (4S)-5-[4-[2-(dimethylamino)acetyl]piperazin-1-yl]-5-oxo-4-[(6-phenylpyridine-2-carbonyl)amino]pentanoate 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 以28.3 mg的产率得到(4S)-5-[4-(N,N-dimethylglycyl)piperazin-1-yl]-5-oxo-4-([(6-phenylpyridin-2-yl)carbonyl]amino)pentanoic acid
  参考文献：
  名称：

  Piperazinyl Glutamate Pyridines as Potent Orally Bioavailable P2Y₁₂ Antagonists for Inhibition of Platelet Aggregation

  摘要：

  Polymer-assisted solution-phase (PASP) parallel library synthesis was used to discover a piperazinyl glutamate pyridine as a P2Y(12) antagonist. Exploitation of this lead provided compounds with excellent inhibition of platelet aggregation its measured in a human platelet rich plasma (PRP) assay. Pharmacokinetic and physiochemical properties were optimized through modifications at the 4-position or the pyridine ring and the terminal nitrogen of the piperazine ring, leading to compound (4S)4-[({4-[4-(methoxymethyl)piperdin-1-yl]-6-phenylpyridin-2-yl}carbonyl)amino]-5-oxo-5-{4-[(pentyloxy)carbonyl]piperazin-1-yl}pentanoic acid 47s with good human PRP potency, selectivity, in vivo efficacy, and oral bioavallability. Compound 47s was selected for further preclinical evaluations.

  DOI：

  10.1021/jm901518t